Navigation Links
Research study explores gene therapy treatment to reduce symptoms of Parkinson's disease
Date:3/8/2011

(CHICAGO) Physicians at Rush University Medical Center are testing a unique gene therapy product called CERE-120 to evaluate if its use can improve the symptoms of Parkinson's disease. Rush is one of 11 sites in the U.S. and the only site in Illinois enrolling patients into the new, double-blinded trial.

CERE-120 is an experimental gene transfer drug being developed by Ceregene, Inc. It contains the human gene for neuturin, a naturally occurring protein also known as a neurotrophic factor. Neurosurgery is used to deliver the neuturin directly to degenerating or dying dopamine neurons in the brain. In earlier studies, neuturin has shown to improve function and repair brain cells that degenerate in Parkinson's disease.

"This gene therapy has the potential to improve the symptoms of Parkinson's disease while also delaying further disease progression," said Dr. Christopher Goetz, director of the Parkinson's Disease and Movement Disorders program at Rush University Medical Center and site principal investigator of the study. "Patients with Parkinson's disease urgently need therapeutic approaches that not only improve symptoms and function, but also to have the ability to favorably modify the underlying disease itself."

Three previous trials demonstrated that CERE-120 was safe in 50 Parkinson's disease patients who were followed for five years. Rush neurological researchers have been involved in all three trials.

"The preliminary data in the Phase I study are encouraging, and the first Phase II trial showed improvement in patients who were assessed under blinded conditions at 15-18 months post treatment," said Goetz.

The new Phase IIb trial will test the efficacy of CERE-120 by delivering an increased dose of the gene therapy to two key areas of the brain called the substantia nigra and the putamen that are damaged by Parkinson's disease. The goal of this new approach is to assure wider distribution of neurturin and increase the likelihood of repairing and protecting brain cells from further degeneration due to Parkinson's disease.

Half of study participants will undergo surgery to receive a dosing of CERE-120. The other half will undergo a placebo surgery. A comparison between these two groups will help distinguish the effects of CERE-120 compared to those that receive placebo

If the study results demonstrate that CERE-120 administration is safe and beneficial, subjects who receive placebo surgery will have the option to have a second surgery to receive a dosing of CERE-120.


'/>"/>

Contact: Deb Song
deb_song@rush.edu
312-942-0588
Rush University Medical Center
Source:Eurekalert

Related medicine news :

1. National Comprehensive Cancer Network and SNM join to advance oncology imaging research
2. LRI awards wide-ranging research grants to drive next generation of scientific discovery in lupus
3. University of South Florida researchers find blood-brain barrier damaged by disease
4. Boston researchers create SMArt platform architecture, launch $5,000 health app competition
5. March of Dimes provides $2.4 million in new funding for preterm birth research
6. Scripps Research and MIT scientists discover class of potent anti-cancer compounds
7. UCLA researchers use nano-Velcro technology to improve capture of circulating cancer cells
8. Helicobacter pylori infection linked to decreased iron levels in otherwise healthy children, according to research at UTHealth
9. Research sheds light on fat digestibility in pigs
10. Aging in place preserves seniors independence, reduces care costs, MU researchers find
11. Elderly see pedestrians half as often as younger drivers, according to Ben-Gurion U. researchers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... 08, 2016 , ... A man who has struggled to quit smoking, a man who has ... determined to find solutions to his problems – and he did. Now Nabat, a serial ... to introduce his breakthrough inventions to the world and better people's lives. His own experience ...
(Date:2/8/2016)... Hilton Head Island, SC (PRWEB) , ... February 08, 2016 , ... ... Head and surrounding areas with a vital new community enrichment program, has teamed up ... to local women and children suffering from intimate abuse. To support all those victimized ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... today that nominations will be accepted February 8, 2016 through May 8, ... Awards include the Information Security Executive® of the Year, which recognizes executives ...
(Date:2/8/2016)... ... February 08, 2016 , ... Discover the Rocky Mountain region’s longest ... and 700 companies. Attendees also get to see the most incredible gardens and ... Home Show , at the Colorado Convention Center - 700 14th St. Denver CO, ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... speaking on how healthcare companies can use newly released government data on populations ... a population and intervene and capture the value they create to succeed in ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... 2016 The life of Dr. Jan Vilcek ... anything but ordinary.  Twists of fate, combined with sheer grit, ... the constraints of communist Czechoslovakia to New York ... on to make history by playing a key role in ... the world, Remicade.  Dr. Vilcek brings readers along his improbable ...
(Date:2/9/2016)... 2016 The new report "Global Anti-Bacterial Drugs Market Assessment ... Consulting group reveals that the North America ... 38.9% in 2014 that translated into revenues worth US$ 16,907.3 million. ... , Asia-Pacific , Latin America ... . The global anti-bacterial market is inclined towards ...
(Date:2/8/2016)... , Feb.8, 2016 Alzheimer Diagnostic ... Summary Medical Devices sector report , ... 2015" provides an overview of Alzheimer Diagnostic Tests ... comprehensive information on the pipeline products with comparative ... development. The report reviews major players involved in ...
Breaking Medicine Technology: